uniQure N.V. Payments for Restructuring
uniQure N.V. (QURE) reported Payments for Restructuring of $4.74 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2025-02-27
- uniQure N.V. payments for restructuring for the quarter ending 2024-12-31 was $2.30M.
- uniQure N.V. payments for restructuring for the quarter ending 2018-12-31 was $21.00K, a 97.33% decline year-over-year.
- uniQure N.V. payments for restructuring for the quarter ending 2018-09-30 was $60.00K, a 84.08% decline year-over-year.
- uniQure N.V. payments for restructuring for the quarter ending 2018-06-30 was $168.00K, a 63.32% decline year-over-year.
- uniQure N.V. payments for restructuring for fiscal 2024 was $4.74M, a 211.43% increase from fiscal 2023.
- uniQure N.V. payments for restructuring for fiscal 2023 was $1.52M.
- uniQure N.V. payments for restructuring for fiscal 2018 was $725.00K, a 72.10% decline from fiscal 2017.
- uniQure N.V. payments for restructuring for fiscal 2017 was $2.60M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2024-12-31 | $2.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.74M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $2.44M 10-Q · filed 2024-11-05 | |||
| 2023-12-31 | $1.52M 10-K · filed 2025-02-27 | |||
| 2018-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $81.00K derived: sum of 2 quarters · filed 2019-02-28 | $249.00K derived: sum of 3 quarters · filed 2019-02-28 | $725.00K 10-K · filed 2019-02-28 |
| 2018-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $228.00K derived: sum of 2 quarters · filed 2018-11-06 | $704.00K 10-Q · filed 2018-11-06 | $1.49M derived: sum of 4 quarters · filed 2018-11-06 |
| 2018-06-30 | $168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $644.00K 10-Q · filed 2018-08-08 | $1.43M derived: sum of 3 quarters · filed 2018-08-08 | $1.81M derived: sum of 4 quarters · filed 2018-08-08 |
| 2018-03-31 | $476.00K 10-Q · filed 2018-04-30 | $1.26M derived: sum of 2 quarters · filed 2018-04-30 | $1.64M derived: sum of 3 quarters · filed 2018-04-30 | $2.10M derived: sum of 4 quarters · filed 2018-04-30 |
| 2017-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $1.16M derived: sum of 2 quarters · filed 2018-03-14 | $1.62M derived: sum of 3 quarters · filed 2018-03-14 | $2.60M 10-K · filed 2018-03-14 |
| 2017-09-30 | $377.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $835.00K derived: sum of 2 quarters · filed 2017-11-01 | $1.81M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $458.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $1.44M 10-Q · filed 2017-08-08 | ||
| 2017-03-31 | $977.00K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |